GlassScriptPhysician profile
Mark I Harris
NPI 1649262577
$58,905.46
in general payments reported to CMS, 2019-2025
51 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $13K · 2021: $11K · 2022: $1,854 · 2023: $2,788 · 2024: $3,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,125 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,450 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,125.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,450.00 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $39,254.50 | 2019-2024 | Amyvid |
| Abbvie INC. | $4,542.59 | 2019-2024 | |
| Allergan, INC. | $4,248.69 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $926.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $743.69 | 2019-2024 | |
| Biogen, INC. | $721.51 | 2019-2024 | Tysabri, Vumerity, Avonex |
| Amgen INC. | $687.44 | 2019-2023 | Aimovig |
| Ucb, INC. | $522.70 | 2019-2024 | Briviact, Rystiggo |
| Eisai INC. | $502.36 | 2019-2024 | |
| Acadia Pharmaceuticals INC | $482.27 | 2019-2024 | Nuplazid |
| Upsher-Smith Laboratories LLC | $470.31 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $441.71 | 2019-2024 | Rytary |
| Teva Pharmaceuticals USA, INC. | $416.00 | 2019-2024 | Austedo Xr, Austedo |
| Neurelis, INC. | $411.36 | 2020-2024 | Valtoco |
| Adamas Pharmaceuticals, INC. | $358.73 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.